An Exploratory Trial to Estimate the Proportion of Patients With Tumor Cell Contaminated, Flow Positive Leukapheresis Products Collected With and Without Bortezomib as In-vivo Purging Prior to Autologous Stem Cell Harvest for Multiple Myeloma
Phase of Trial: Phase II
Latest Information Update: 23 Nov 2016
At a glance
- Drugs Bortezomib (Primary)
- Indications Multiple myeloma
- Focus Pharmacodynamics
- 07 Jun 2017 Biomarkers information updated
- 17 Nov 2016 Planned End Date changed from 1 Aug 2018 to 1 Sep 2018.
- 17 Nov 2016 Planned primary completion date changed from 1 Feb 2018 to 1 Mar 2018.